NASDAQ:TXMD - TherapeuticsMD Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.6150 -0.09 (-1.34 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$6.6150
Today's Range$6.59 - $6.85
52-Week Range$4.34 - $7.66
Volume1.38 million shs
Average Volume1.68 million shs
Market Capitalization$1.45 billion
P/E Ratio-17.88
Dividend YieldN/A
Beta1.38
TherapeuticsMD logoTherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Debt-to-Equity RatioN/A
Current Ratio7.61
Quick Ratio7.51

Price-To-Earnings

Trailing P/E Ratio-17.88
Forward P/E Ratio-12.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.78 million
Price / Sales85.38
Cash FlowN/A
Price / CashN/A
Book Value$0.60 per share
Price / Book11.03

Profitability

EPS (Most Recent Fiscal Year)($0.37)
Net Income$-76,920,000.00
Net Margins-483.98%
Return on Equity-66.77%
Return on Assets-60.12%

Miscellaneous

Employees173
Outstanding Shares216,580,000
Market Cap$1,453.28

TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) issued its quarterly earnings results on Thursday, May, 3rd. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The firm had revenue of $3.77 million for the quarter, compared to analysts' expectations of $4.18 million. TherapeuticsMD had a negative net margin of 483.98% and a negative return on equity of 66.77%. TherapeuticsMD's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.11) EPS. View TherapeuticsMD's Earnings History.

What price target have analysts set for TXMD?

9 brokerages have issued 1 year price targets for TherapeuticsMD's stock. Their forecasts range from $6.00 to $28.00. On average, they anticipate TherapeuticsMD's share price to reach $14.6250 in the next year. This suggests a possible upside of 121.1% from the stock's current price. View Analyst Ratings for TherapeuticsMD.

What is the consensus analysts' recommendation for TherapeuticsMD?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 59,072,667 shares, an increase of 1.0% from the June 15th total of 59,676,731 shares. Based on an average trading volume of 2,582,333 shares, the days-to-cover ratio is presently 22.9 days. Approximately 34.0% of the company's shares are short sold. View TherapeuticsMD's Current Options Chain.

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)
  • Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)
  • Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)
  • Mr. Daniel Alan Cartwright, CFO, Treasurer & Principal Accounting Officer (Age 60)
  • Mr. Mitchell L. Krassan, Chief Strategy Officer and Exec. VP (Age 52)

Has TherapeuticsMD been receiving favorable news coverage?

Media coverage about TXMD stock has trended positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TherapeuticsMD earned a news sentiment score of 0.26 on Accern's scale. They also gave headlines about the company an impact score of 44.75 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.20%), Cornerstone Wealth Management LLC (0.02%), Affiance Financial LLC (0.01%) and Fox Run Management L.L.C. (0.01%). View Institutional Ownership Trends for TherapeuticsMD.

Which major investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for TherapeuticsMD.

Which major investors are buying TherapeuticsMD stock?

TXMD stock was acquired by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, Affiance Financial LLC and Fox Run Management L.L.C.. View Insider Buying and Selling for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $6.6150.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $1.45 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.